With so many patients choosing BTK inhibitors for their Waldenstrom Macroglobulinemia treatment, and new WM treatments in development, it is difficult to keep up with so much new information. This is your chance to get Dr. Jorge Castillo's expert info about BTK inhibitors, long term goals and monitoring; what to do, what not to do; complications; and even some success stories.
Speaker: Dr. Jorge Castillo
Associate Professor at Harvard Medical School and Clinical Director of the Bing Center for WM at Dana-Farber Cancer Institute